Business · Companies · 1 day ago
TrivarX shifts focus to brain cancer imaging under new CEO
TrivarX, an Australian biotech company, is shifting its focus to imaging cancers of the brain and spinal cord.
It acquired Stabl-Im in November 2025 and appointed Dr Danielle Meyrick as CEO to lead its development.
Stabl-Im is designed to add information about tumour activity to high-resolution MRI images without using radioactive agents.
MRI can show detailed images of the brain, but TrivarX says Stabl-Im could provide clinicians with more information about how a tumour is behaving.
That information may help clinicians assess treatment responses and make decisions about care.
The technology is intended to complement existing imaging methods such as MRI and PET, not replace them.
TrivarX is preparing a Phase I clinical trial to learn more about how Stabl-Im works.
TrivarX is shifting its focus to central nervous system cancer imaging after acquiring the radiation-free Stabl-Im technology.
New CEO Dr Danielle Meyrick is leading the company’s strategic reset and Stabl-Im’s development.
The technology is designed to add information about tumour activity to MRI images and help inform treatment decisions.
TrivarX is preparing for a Phase I clinical trial to learn more about Stabl-Im’s biophysical behaviour.
- Who
- TrivarX, led by CEO Dr Danielle Meyrick, is developing Stabl-Im.
- What
- The company is shifting towards brain and other central nervous system cancer imaging using the radiation-free technology.
- When
- TrivarX announced an exclusive option in October 2025 and acquired Stabl-Im in November 2025. The article was published on October 11, 2026.
- Where
- The focus is imaging cancers affecting the brain and spinal cord. A company location is not stated.
- Why
- TrivarX aims to help track cancer patients’ responses to treatment, identify tumours sooner and provide clinicians with more information for treatment decisions.
This story does not have two clearly opposing sides.
TrivarX announced an exclusive option to acquire Stabl-Im and paid Nucleics a $250,000 non-refundable fee.
TrivarX acquired the Stabl-Im technology from Nucleics.
Stockhead reported that TrivarX was preparing for a Phase I clinical trial and pursuing its imaging focus under CEO Danielle Meyrick.
- Technology
- Stabl-Im, described as radiation-free
- Imaging focus
- Central nervous system cancers, including cancers affecting the brain and spinal cord
- CEO
- Dr Danielle Meyrick
- Option fee
- $250,000 non-refundable fee paid to Nucleics
- Performance shares
- 750 million TRI shares across two tranches, tied to development milestones
- Clinical development
- TrivarX is preparing for a Phase I clinical trial
What people are saying
The Stabl-Im technology provides an opportunity to better track how cancer patients respond to treatment and identify tumours sooner and safer using just MRI imaging.
I am very happy to see TrivarX advancing this exciting technology into the clinic.
We don’t have the handling and safety issues or the decay issues associated with radioisotopes, which to me makes it a genuinely attractive technology.
Danielle is the right person to take Stabl-Im forward.
Sources
Related news
No details available about retirement changes
Perth rental vacancy rate falls to a two-year low
ASX falls as China lithium supply news weighs on miners and oil prices rise
Identifai Genetics lists on the ASX after raising $10 million
Brokers see potential gains for NexGen Energy and Viva Energy shares
Delorean signs non-binding $20m financing agreement with Westpac
IMF oil-price scenario could push Australian petrol up 30 cents a litre
Evolution Mining compared with Northern Star Resources for investors
IMF expects Australia’s unemployment rate to rise to 4.7% in 2027
Stelar begins 3,500-metre tungsten drilling in Northern Territory
Shell says Australia’s gas reserve plan risks market failure
